相关实验视频

Updated: Jul 5, 2025

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis

Published on: July 11, 2013

基于PROTAC的JAK1/JAK2降解剂用于局部治疗亚托皮炎

Junchao Wu¹, Lisha Li¹, Quangang Zhu¹

¹Shanghai Skin Disease Hospital, School of Medicine, Tongji University, 1278 Baode Road, Shanghai 200443, China; School of Medicine, Shanghai University, 99 Shangda Road, Shanghai 200444, China.

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

|January 23, 2024

概括

新的局部JAK1/JAK2降解剂 (JAPT) 通过降解Janus激酶 (JAK) 有效地治疗亚托皮炎 (AD). 这种基于PROTAC的方法显示了AD治疗的希望,与传统抑制剂相比,疗效提高和剂量减少.

科学领域:

皮肤病学皮肤病学
免疫学免疫学免疫学
药理学药理学是指药理学的学科.

背景情况:

亚托皮炎 (AD) 是一种常见的慢性炎症性皮肤疾病.
简氏激酶 (JAK) 信号传导与AD病变发生有关,调节炎症基因和免疫反应.
局部雅努斯激酶 (JAK) 抑制剂在治疗阿尔茨海默病方面存在局限性,原因是皮肤结构.

研究的目的:

开发和评估用于治疗阿托皮性皮炎的新型局部JAK1/JAK2降解剂 (JAPT).
评估JAPT在降解JAK1/JAK2和抑制AD炎症通路中的有效性.

主要方法:

合成JAK1/JAK2降解剂 (JAPT) 使用蛋白质降解向嵌合体 (PROTAC) 技术.
将JAPT制成用于皮肤的局部制剂.
在体外评估JAPT对促炎性细胞因子释放和JAK降解的影响.
在动物模型中,对JAPT降解JAK1/JAK2,抑制适应性免疫力和降低AD严重性的有效性进行了体内评估.

主要成果:

在实验室中,JAPT有效促进了JAK1/JAK2的降解,从而抑制了促炎性细胞因子的释放,并减少了炎症.
在体内研究证实了JAPT降解JAK1/JAK2的能力,显著抑制I,II和III类型的适应性免疫力.
局部JAPT应用导致AD严重程度明显改善,包括皮肤病变清除和SCORAD得分降低.

结论:

JAPT代表了对亚托皮性皮炎的有希望的治疗策略,比传统的局部JAK抑制剂提供了更高的疗效.
基于JAPT的PROTAC方法提供了一种新的局部治疗方法,针对AD的JAK-STAT途径.
由于向蛋白质降解,JAPT证明了有效的AD治疗的潜力,其频率和剂量较低.

关键词:

亚托邦性皮肤炎 (Atopic Dermatitis) 是一种不良的疾病.降解剂降解剂是一种降解剂.炎症性细胞因子是可以引起炎症的.亚努斯酶是亚努斯酶的一种.局部治疗局部治疗

更多相关视频

Resolving Water, Proteins, and Lipids from In Vivo Confocal Raman Spectra of Stratum Corneum through a Chemometric Approach

Resolving Water, Proteins, and Lipids from In Vivo Confocal Raman Spectra of Stratum Corneum through a Chemometric Approach

Published on: September 26, 2019

Effects of Exposure of Formaldehyde to a Rat Model of Atopic Dermatitis Induced by Neonatal Capsaicin Treatment

Effects of Exposure of Formaldehyde to a Rat Model of Atopic Dermatitis Induced by Neonatal Capsaicin Treatment

Published on: September 27, 2017

相关概念视频

The JAK-STAT Signaling Pathway

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...